	US 12,441,794 B2
	Antibodies for the diagnosis and treatment of B-cell acute lymphoblastic leukemia
Andrei Thomas-Tikhonenko, Philadelphia, PA (US); and Sisi Zheng, Philadelphia, PA (US)
Assigned to The Children's Hospital of Philadelphia, Philadelphia, PA (US)
Appl. No. 17/630,361
Filed by THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US)
PCT Filed Jul. 29, 2020, PCT No. PCT/US2020/043939 § 371(c)(1), (2) Date Jan. 26, 2022, PCT Pub. No. WO2021/021846, PCT Pub. Date Feb. 4, 2021.
Claims priority of provisional application 62/879,825, filed on Jul. 29, 2019.
Prior Publication US 2022/0289841 A1, Sep. 15, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/02 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/16 (2006.01)

CPC C07K 16/2803 (2013.01) [C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C12N 5/16 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/569 (2013.01); C07K 2319/03 (2013.01)]

24 Claims

1. A method of treating acute lymphoblastic leukemia (ALL) comprising contacting a ALL cancer cell in a subject with an antibody, antibody fragment or antibody derivative that binds selectively to CD22-Δex5-6 protein, or to a peptide having the sequence of QLNVKHPPKKVTTVIQNP (SEQ ID NO: 1), wherein the antibody, antibody fragment or antibody derivative comprises heavy and light chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOS: 2-4 and 5-7, respectively.